Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Oct 17;10(10):CD000188.
doi: 10.1002/14651858.CD000188.pub2.

Steroid sex hormones for lower limb atherosclerosis

Jackie Price  1 , Gillian C Leng
Affiliations
Meta-Analysis

Steroid sex hormones for lower limb atherosclerosis

Jackie Price et al. Cochrane Database Syst Rev. .

Abstract

Background: There is accumulating evidence that steroid sex hormones have a beneficial effect on a number of risk factors for peripheral arterial disease.

Objectives: The objective of this review was to determine whether exogenous steroid sex hormones are an effective treatment for patients with lower limb atherosclerosis.

Search methods: For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2012) and CENTRAL 2012, Issue 7. There were no language restrictions.

Selection criteria: We selected randomised or quasi-randomised controlled trials of steroid sex hormones in patients with lower limb atherosclerosis.

Data collection and analysis: Both authors extracted data and assessed trial quality independently. Whenever possible investigators were contacted to obtain information needed for the review that could not be found in published reports.

Main results: Four trials appeared to meet the inclusion criteria, but one was excluded because of poor methodology. The three remaining trials compared testosterone treatment with placebo in a total of 109 subjects with intermittent claudication or critical leg ischaemia. The most recent trial to meet the inclusion criteria dated from 1971. No trials were available which investigated the potentially beneficial effects of oestrogenic hormones in women with lower limb atherosclerosis.Testosterone therapy produced no significant improvement in tests of walking distance or in a variety of other objective tests for peripheral arterial disease, including venous filling time, muscle blood flow and plethysmography. The relative risk for subjective improvement in symptoms using the combined trial results was also non-significant (relative risk (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48).

Authors' conclusions: There is no evidence to date that short-term testosterone treatment is beneficial in subjects with lower limb atherosclerosis. However, this might reflect limited data rather than the lack of a real effect.

PubMed Disclaimer

Conflict of interest statement

JF Price: None known GC Leng: None known

Figures

1.1
1.1. Analysis
Comparison 1 Testosterone versus placebo, Outcome 1 Subjective improvement in symptoms of intermittent claudication.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Dohn 1968 {published data only}
    1. Dohn K, Hvidt V, Nielsen J, Palm L. Testosterone therapy in obliterating arterial lesions in the lower limbs. Angiology 1968;19(6):342‐50. - PubMed
    1. Hvidt V, Dohn K, Lund J, Nielsen J, Palm L. Testosterone treatment of obliterative arterial lesions in the legs [Testosteronbehandling af obliterende arterielidelser pa underekstremiteterne]. Ugeskrift för Laeger 1965;127(36):1116‐23. - PubMed
Genster 1971 {published data only}
    1. Genster HG, Oram V. Arterial insufficiency in the lower extremities treated with drugs [Arteriel insufficiens i underekstremiteterne behandlet medikamentelt]. Ugeskrift för Laeger 1971;133:244‐6. - PubMed
Hentzer 1967 {published data only}
    1. Hentzer E, Madsen PC. Testosterone in the treatment of arterial insufficiency of the lower limbs [Testosteron ved arteriel insufficiens i underekstremiteterne]. Nordisk Medicin 1966;76(45):1307‐112. - PubMed
    1. Hentzer E, Madsen PC. Testosterone in the treatment of arterial insufficiency of the lower limbs. Scandinavian Journal of Clinical & Laboratory Investigations 1967;Supplement 99:198‐206. - PubMed

References to studies excluded from this review

Albrechtsen 1972 {published data only}
    1. Albrechtsen O, Barfod B, Barfod E, Laursen NPR, Nordentoft B, Yde H. Hormonal treatment of arterial insufficiency in the lower extremities. Danish Medical Bulletin 1972;19:157‐9. - PubMed

References to studies awaiting assessment

NCT00504712 {published data only (unpublished sought but not used)}
    1. Stanworth R. Testosterone for Peripheral Vascular Disease [A randomised, double blind, placebo controlled, parallel pilot study to test the effect of testosterone treatment on peripheral vascular disease in hypogonadal men with type 2 Diabetes Mellitus]. http://clinicaltrials.gov/show/NCT00504712 2007. [NCT00504712]

Additional references

Bonithon‐Kopp 1988
    1. Bonithon‐Kopp C, Scarabin P‐Y, Bara L, Castanier M, Jacqueson A, Roger M. Relationship between sex hormones and haemostatic factors in healthy middle‐aged men. Atherosclerosis 1988;71(1):71‐6. - PubMed
Fearnley 1962
    1. Fearnley GR, Chakrabarti R. Increase of blood fibrinolytic activity by testosterone. Lancet 1962;1:128‐32. - PubMed
Grady 2002
    1. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow‐up (HERS II). JAMA 2002;288(1):99‐101. - PubMed
Herrington 2000
    1. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine 2000;343(8):522‐9. - PubMed
Hsia 2004
    1. Hsia J, Criqui MH, Rodabough RJ, Langer RD, Phillips LS, Allison M, et al. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. Circulation 2004;109(5):620‐6. - PubMed
Hulley 1998
    1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomised trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280(7):605‐13. - PubMed
Kalin 1990
    1. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids 1990;55(8):330‐52. - PubMed
Khan 2000
    1. Khan MA, Heagerty AM, Kitchener H, McNamee R, Cherry NM, Hannaford P. Oestrogen and women's heart disease: ESPRIT‐UK. QJM 2000;93:699‐700. - PubMed
Khaw 1991
    1. Khaw KT, Barrett‐Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arteriosclerosis and Thrombosis 1991;11(3):489‐94. - PubMed
Lassen 1964
    1. Lassen NA, Lindbjerg IF, Munck O. Measurement of blood‐flow through skeletal muscle by intramuscular injection of Xenon‐133. Lancet 1964;1:686‐9. - PubMed
Leng 1993
    1. Leng GC, Fowkes FGR. The epidemiology of peripheral arterial disease. Vascular Medicine Reviews 1993;4:5‐18.
Manolio 1993
    1. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993;88(5 part 1):2163‐71. - PubMed
Matsumoto 1990
    1. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose‐dependent supression of luteinizing hormone, follicle‐stimulating hormone, and sperm production. Journal of Clinical Endocrinology and Metabolism 1990;70(1):282‐7. - PubMed
Nabulsi 1993
    1. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone‐replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. New England Journal of Medicine 1993;328(15):1069‐75. - PubMed
Oliver 1956
    1. Oliver MF, Boyd GS. Endocrine aspects of coronary sclerosis. Lancet 1956;2:1273‐6. - PubMed
PEPI Trial 1995
    1. Anonymous. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273(3):199‐208. - PubMed
Stampfer 1991
    1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991;20(1):47‐63. - PubMed
WHI Study Group 1998
    1. Anonymous. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials 1998;19(1):61‐109. - PubMed

References to other published versions of this review

Price 1997
    1. Price JF, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 1997, Issue 1. [DOI: 10.1002/14651858.CD000188] - DOI - PubMed
Price 2001
    1. Price J, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD000188] - DOI

Publication types